BioArctic AB and Eisai Co., Ltd. have entered into a collaboration to research BAN2802, a potential Alzheimer's treatment.

The treatment merges BioArctic's BrainTransporter technology with an undisclosed Alzheimer's drug candidate.

Eisai holds the responsibility to analyze the research data and may decide to license BAN2802 for Alzheimer's treatment.

The collaboration is part of a continuous partnership aimed at developing next-generation disease-modifying Alzheimer's treatments.

Both companies will share the costs for the research evaluation of BAN2802.

This partnership follows their previous success in developing Leqembi (lecanemab), the first approved drug to slow the progression of early Alzheimer's.